Journal article
Plasma p217 tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
V Doré, JD Doecke, ZS Saad, G Triana-Baltzer, R Slemmon, N Krishnadas, P Bourgeat, K Huang, S Burnham, C Fowler, SR Rainey-Smith, AI Bush, L Ward, J Robertson, RN Martins, CL Masters, VL Villemagne, J Fripp, HC Kolb, CC Rowe
Alzheimer S and Dementia Diagnosis Assessment and Disease Monitoring | Published : 2022
DOI: 10.1002/dad2.12307
Abstract
Introduction: We evaluated a new Simoa plasma assay for phosphorylated tau (P-tau) at aa217 enhanced by additional p-tau sites (p217+tau). Methods: Plasma p217+tau levels were compared to 18F-NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and 18F-MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Results: Compared to Aβ− CU, the plasma levels of p217+tau increased 2-fold in Aβ+ CU and 3.5-fold in Aβ+ CI. In Aβ− the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P =.67 (CI, P =.64; CU, P =.45) and tau SUVRMT P =.63 (CI, P =.69; CU, P =.34). Area under curve (AUC) for Alzheimer'..
View full abstractGrants
Awarded by Commonwealth Scientific and Industrial Research Organisation
Funding Acknowledgements
Australian Federal Government; NHMRC, Grant/Award Numbers: APP1132604, APP1140853, APP1152623